LivaNova Stock Forecast, Price & News

-1.19 (-1.40 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume172,176 shs
Average Volume400,377 shs
Market Capitalization$4.11 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LivaNova logo

About LivaNova

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.


September 11, 2021 |
Zacks: Brokerages Expect LivaNova PLC (NASDAQ:LIVN) to Post $0.45 EPS
Zacks: Brokerages Expect LivaNova PLC (NASDAQ:LIVN) to Post $0.45 EPS
September 10, 2021 |
LivaNova (NASDAQ:LIVN) Shares Gap Up to $83.67
LivaNova (NASDAQ:LIVN) Shares Gap Up to $83.67
September 3, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.28 out of 5 stars

Medical Sector

270th out of 1,352 stocks

Electromedical Equipment Industry

7th out of 31 stocks

Analyst Opinion: 2.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

LivaNova (NASDAQ:LIVN) Frequently Asked Questions

Is LivaNova a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LivaNova stock.
View analyst ratings for LivaNova
or view top-rated stocks.

What stocks does MarketBeat like better than LivaNova?

Wall Street analysts have given LivaNova a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but LivaNova wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting LivaNova?

LivaNova saw a increase in short interest in August. As of August 13th, there was short interest totaling 2,620,000 shares, an increase of 20.2% from the July 29th total of 2,180,000 shares. Based on an average trading volume of 356,600 shares, the days-to-cover ratio is presently 7.3 days.
View LivaNova's Short Interest

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for LivaNova

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday, July, 28th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.19. The business earned $264.50 million during the quarter, compared to analysts' expectations of $241.73 million. LivaNova had a negative net margin of 37.15% and a positive trailing twelve-month return on equity of 8.44%.
View LivaNova's earnings history

How has LivaNova's stock price been impacted by COVID-19?

LivaNova's stock was trading at $62.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LIVN shares have increased by 33.7% and is now trading at $83.78.
View which stocks have been most impacted by COVID-19

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY 2021 earnings guidance on Monday, September, 13th. The company provided earnings per share guidance of $1.750-$2.050 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.770. The company issued revenue guidance of -.

What price target have analysts set for LIVN?

4 analysts have issued 12 month target prices for LivaNova's stock. Their forecasts range from $84.00 to $117.00. On average, they expect LivaNova's share price to reach $101.00 in the next year. This suggests a possible upside of 20.6% from the stock's current price.
View analysts' price targets for LivaNova
or view top-rated stocks among Wall Street analysts.

Who are LivaNova's key executives?

LivaNova's management team includes the following people:
  • Damien McDonald, Chief Executive Officer & Executive Director
  • Marco Dolci, Head-Global Operations, R&D
  • Alex Shvartsburg, Chief Financial Officer
  • Keyna P. Skeffington, Secretary, Senior Vice President & General Counsel
  • Matt J. Dodds, Senior Vice President-Corporate Development

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova CEO Damien McDonald on Damien McDonald has an approval rating of 77% among LivaNova's employees.

Who are some of LivaNova's key competitors?

What other stocks do shareholders of LivaNova own?

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.22%), Primecap Management Co. CA (8.21%), Barrow Hanley Mewhinney & Strauss LLC (4.53%), State Street Corp (4.02%), Vanguard Group Inc. (2.54%) and Maverick Capital Ltd. (2.34%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends for LivaNova

Which major investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Diamond Hill Capital Management Inc., UBS Asset Management Americas Inc., Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., Sector Gamma AS, Franklin Resources Inc., and BP PLC. Company insiders that have sold LivaNova company stock in the last year include Daniel Jeffrey Moore, and Marco Dolci.
View insider buying and selling activity for LivaNova
or view top insider-selling stocks.

Which major investors are buying LivaNova stock?

LIVN stock was acquired by a variety of institutional investors in the last quarter, including Sachem Head Capital Management LP, State Street Corp, P Schoenfeld Asset Management LP, Balyasny Asset Management LLC, Northern Trust Corp, Bridger Management LLC, Dimensional Fund Advisors LP, and Greenlight Capital Inc..
View insider buying and selling activity for LivaNova
or or view top insider-buying stocks.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $83.78.

How much money does LivaNova make?

LivaNova has a market capitalization of $4.11 billion and generates $934.20 million in revenue each year. The company earns $-345,010,000.00 in net income (profit) each year or $1.27 on an earnings per share basis.

How many employees does LivaNova have?

LivaNova employs 4,000 workers across the globe.

What is LivaNova's official website?

The official website for LivaNova is

Where are LivaNova's headquarters?

LivaNova is headquartered at 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 442033250660 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.